{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:54:39Z","timestamp":1781823279782,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":51,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA292020"],"award-info":[{"award-number":["R01CA292020"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH1910088"],"award-info":[{"award-number":["W81XWH1910088"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02281-0","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:19:07Z","timestamp":1777450747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic targeting of RAGE\/STAT3 signaling abrogates S100A7-driven breast tumorigenicity and immune suppression"],"prefix":"10.1186","volume":"28","author":[{"given":"Pratyusha","family":"Ghanta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajeet K.","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho-Hao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Charan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh R.","family":"Koshre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashwat","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Adorno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayush Arpit","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanisha","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne O.","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh K.","family":"Ganju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"2281_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030482","author":"EE Newton","year":"2022","unstructured":"Newton EE, et al. Molecular targets of triple-negative breast cancer: where do we stand? Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14030482.","journal-title":"Cancers (Basel)"},{"key":"2281_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/biom13081207","author":"AG Chapdelaine","year":"2023","unstructured":"Chapdelaine AG, Sun G. Challenges and opportunities in developing targeted therapies for triple negative breast cancer. Biomolecules. 2023. https:\/\/doi.org\/10.3390\/biom13081207.","journal-title":"Biomolecules"},{"key":"2281_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.919072","volume":"12","author":"C Luo","year":"2022","unstructured":"Luo C, et al. Progress and prospect of immunotherapy for triple-negative breast cancer. Front Oncol. 2022;12:919072.","journal-title":"Front Oncol"},{"issue":"6","key":"2281_CR4","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1158\/0008-5472.CAN-14-2161","volume":"75","author":"MW Nasser","year":"2015","unstructured":"Nasser MW, et al. RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment. Cancer Res. 2015;75(6):974\u201385.","journal-title":"Cancer Res"},{"issue":"1","key":"2281_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13046-021-02221-0","volume":"41","author":"S Mishra","year":"2022","unstructured":"Mishra S, et al. cPLA2 blockade attenuates S100A7-mediated breast tumorigenicity by inhibiting the immunosuppressive tumor microenvironment. J Exp Clin Cancer Res. 2022;41(1):54.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"2281_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/bcr816","volume":"6","author":"ED Emberley","year":"2004","unstructured":"Emberley ED, Murphy LC, Watson PH. S100A7 and the progression of breast cancer. Breast Cancer Res. 2004;6(4):153\u20139.","journal-title":"Breast Cancer Res"},{"key":"2281_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175861","volume":"954","author":"X Dai","year":"2023","unstructured":"Dai X, et al. A specific RAGE-binding peptide inhibits triple negative breast cancer growth through blocking of Erk1\/2\/NF-kappaB pathway. Eur J Pharmacol. 2023;954:175861.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"2281_CR8","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1158\/0008-5472.CAN-15-2770","volume":"76","author":"LM Jones","year":"2016","unstructured":"Jones LM, et al. STAT3 establishes an immunosuppressive microenvironment during the early stages of breast carcinogenesis to promote tumor growth and metastasis. Cancer Res. 2016;76(6):1416\u201328.","journal-title":"Cancer Res"},{"key":"2281_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040621","author":"MG Muoio","year":"2021","unstructured":"Muoio MG, et al. Activation of the S100A7\/RAGE pathway by IGF-1 contributes to angiogenesis in breast cancer. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13040621.","journal-title":"Cancers (Basel)"},{"issue":"18","key":"2281_CR10","doi-asserted-by":"publisher","first-page":"7031","DOI":"10.1073\/pnas.1113865109","volume":"109","author":"R Kang","year":"2012","unstructured":"Kang R, et al. The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci U S A. 2012;109(18):7031\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2281_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41523-023-00564-9","volume":"9","author":"M Magna","year":"2023","unstructured":"Magna M, et al. RAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer. npj Breast Cancer. 2023;9(1):59.","journal-title":"npj Breast Cancer"},{"issue":"1","key":"2281_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41419-023-05576-8","volume":"14","author":"YH Su","year":"2023","unstructured":"Su YH, et al. Obesity promotes radioresistance through SERPINE1-mediated aggressiveness and DNA repair of triple-negative breast cancer. Cell Death Dis. 2023;14(1):53.","journal-title":"Cell Death Dis"},{"issue":"5","key":"2281_CR13","first-page":"1875","volume":"44","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Lei L, Jing D. Knockdown of SERPINE1 reverses resistance of triple\u2011negative breast cancer to paclitaxel via suppression of VEGFA. Oncol Rep. 2020;44(5):1875\u201384.","journal-title":"Oncol Rep"},{"issue":"8","key":"2281_CR14","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1016\/j.celrep.2018.10.082","volume":"25","author":"MH Kubala","year":"2018","unstructured":"Kubala MH, et al. Plasminogen activator inhibitor-1 promotes the recruitment and polarization of macrophages in cancer. Cell Rep. 2018;25(8):2177-2191 e7.","journal-title":"Cell Rep"},{"key":"2281_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12975","author":"T Wilkie","year":"2021","unstructured":"Wilkie T, et al. Lipopolysaccharide from the commensal microbiota of the breast enhances cancer growth: role of S100A7 and TLR4. Mol Oncol. 2021. https:\/\/doi.org\/10.1002\/1878-0261.12975.","journal-title":"Mol Oncol"},{"issue":"5","key":"2281_CR16","first-page":"00829","volume":"8","author":"E Dordet-Frisoni","year":"2022","unstructured":"Dordet-Frisoni E, et al. Impacts of Mycoplasma agalactiae restriction-modification systems on pan-epigenome dynamics and genome plasticity. Microb Genom. 2022;8(5):00829.","journal-title":"Microb Genom"},{"issue":"3","key":"2281_CR17","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202153509","volume":"23","author":"X Xu","year":"2022","unstructured":"Xu X, et al. Myeloid-derived growth factor (MYDGF) protects bone mass through inhibiting osteoclastogenesis and promoting osteoblast differentiation. EMBO Rep. 2022;23(3):e53509.","journal-title":"EMBO Rep"},{"key":"2281_CR18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s42003-019-0550-z","volume":"2","author":"AA Garg","year":"2019","unstructured":"Garg AA, et al. Electromagnetic fields alter the motility of metastatic breast cancer cells. Commun Biol. 2019;2:303.","journal-title":"Commun Biol"},{"issue":"6","key":"2281_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106904","volume":"26","author":"CH Lin","year":"2023","unstructured":"Lin CH, et al. CD200R signaling contributes to unfavorable tumor microenvironment through regulating production of chemokines by tumor-associated myeloid cells. iScience. 2023;26(6):106904.","journal-title":"iScience"},{"key":"2281_CR20","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.biopha.2017.02.110","volume":"89","author":"G Rai","year":"2017","unstructured":"Rai G, et al. Evaluation of growth inhibitory response of Resveratrol and Salinomycin combinations against triple negative breast cancer cells. Biomed Pharmacother. 2017;89:1142\u201351.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"2281_CR21","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1093\/annonc\/mdu247","volume":"25","author":"K Hashimoto","year":"2014","unstructured":"Hashimoto K, et al. Activated PI3K\/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer. Ann Oncol. 2014;25(10):1973\u20139.","journal-title":"Ann Oncol"},{"issue":"7","key":"2281_CR22","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/sj.jid.5700210","volume":"126","author":"R Wolf","year":"2006","unstructured":"Wolf R, et al. The mouse S100A15 ortholog parallels genomic organization, structure, gene expression, and protein-processing pattern of the human S100A7\/A15 subfamily during epidermal maturation. J Invest Dermatol. 2006;126(7):1600\u20138.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"2281_CR23","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1002\/cncr.25054","volume":"116","author":"HY Yhim","year":"2010","unstructured":"Yhim HY, et al. Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy. Cancer. 2010;116(12):2890\u2013901.","journal-title":"Cancer"},{"key":"2281_CR24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2026507118","author":"K Mrouj","year":"2021","unstructured":"Mrouj K, et al. Ki-67 regulates global gene expression and promotes sequential stages of carcinogenesis. Proc Natl Acad Sci U S A. 2021. https:\/\/doi.org\/10.1073\/pnas.2026507118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2281_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015332","author":"A Kotsifaki","year":"2023","unstructured":"Kotsifaki A, et al. Unveiling the immune microenvironment\u2019s role in breast cancer: a glimpse into promising frontiers. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms242015332.","journal-title":"Int J Mol Sci"},{"issue":"Pt 23","key":"2281_CR26","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1242\/jcs.116392","volume":"125","author":"FR Balkwill","year":"2012","unstructured":"Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125(Pt 23):5591\u20136.","journal-title":"J Cell Sci"},{"issue":"5","key":"2281_CR27","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541\u201350.","journal-title":"Nat Med"},{"issue":"11","key":"2281_CR28","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1158\/1535-7163.MCT-23-0303","volume":"22","author":"M Aleckovic","year":"2023","unstructured":"Aleckovic M, et al. Combination therapies to improve the efficacy of immunotherapy in triple-negative breast cancer. Mol Cancer Ther. 2023;22(11):1304\u201318.","journal-title":"Mol Cancer Ther"},{"key":"2281_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113194","author":"K Kashfi","year":"2021","unstructured":"Kashfi K, Kannikal J, Nath N. Macrophage reprogramming and cancer therapeutics: role of iNOS-derived NO. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10113194.","journal-title":"Cells"},{"key":"2281_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2013.00144","volume":"4","author":"MA Rahat","year":"2013","unstructured":"Rahat MA, Hemmerlein B. Macrophage-tumor cell interactions regulate the function of nitric oxide. Front Physiol. 2013;4:144.","journal-title":"Front Physiol"},{"key":"2281_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.753477","author":"K Kaul","year":"2021","unstructured":"Kaul K, et al. Slit2-mediated metabolic reprogramming in bone marrow-derived macrophages enhances antitumor immunity. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.753477.","journal-title":"Front Immunol"},{"issue":"1","key":"2281_CR32","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1007\/s12672-025-03745-z","volume":"16","author":"S Yan","year":"2025","unstructured":"Yan S, Sun X, Wang K. From cold to hot tumors: feasibility of applying therapeutic insights to TNBC. Discov Oncol. 2025;16(1):1942.","journal-title":"Discov Oncol"},{"key":"2281_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1630464","volume":"15","author":"Z Zhou","year":"2025","unstructured":"Zhou Z, Zhou Q. Immunotherapy resistance in triple-negative breast cancer: molecular mechanisms, tumor microenvironment, and therapeutic implications. Front Oncol. 2025;15:1630464.","journal-title":"Front Oncol"},{"issue":"4","key":"2281_CR34","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.drudis.2021.01.002","volume":"26","author":"S Kumar","year":"2021","unstructured":"Kumar S, et al. Tumor-infiltrating CD8(+) T cell antitumor efficacy and exhaustion: molecular insights. Drug Discov Today. 2021;26(4):951\u201367.","journal-title":"Drug Discov Today"},{"key":"2281_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa407","author":"T Li","year":"2020","unstructured":"Li T, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020. https:\/\/doi.org\/10.1093\/nar\/gkaa407.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"2281_CR36","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"key":"2281_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2172-12-43","volume":"12","author":"B Wang","year":"2011","unstructured":"Wang B, et al. Transition of tumor-associated macrophages from MHC class II(hi) to MHC class II(low) mediates tumor progression in mice. BMC Immunol. 2011;12:43.","journal-title":"BMC Immunol"},{"issue":"20","key":"2281_CR38","doi-asserted-by":"publisher","first-page":"5255","DOI":"10.1158\/0008-5472.CAN-20-3909","volume":"81","author":"DK Ahirwar","year":"2021","unstructured":"Ahirwar DK, et al. Slit2 inhibits breast cancer metastasis by activating M1-like phagocytic and antifibrotic macrophages. Cancer Res. 2021;81(20):5255\u201367.","journal-title":"Cancer Res"},{"issue":"17","key":"2281_CR39","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1073\/pnas.1121623109","volume":"109","author":"SB Willingham","year":"2012","unstructured":"Willingham SB, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012;109(17):6662\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2281_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1213891","volume":"14","author":"L Li","year":"2023","unstructured":"Li L, et al. Identification and validation of SERPINE1 as a prognostic and immunological biomarker in pan-cancer and in ccRCC. Front Pharmacol. 2023;14:1213891.","journal-title":"Front Pharmacol"},{"key":"2281_CR41","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1016\/j.csbj.2021.07.014","volume":"19","author":"B Gyorffy","year":"2021","unstructured":"Gyorffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J. 2021;19:4101\u20139.","journal-title":"Comput Struct Biotechnol J"},{"issue":"1","key":"2281_CR42","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61.","journal-title":"Breast Cancer Res"},{"issue":"7","key":"2281_CR43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.21037\/atm.2020.03.194","volume":"8","author":"S Zhao","year":"2020","unstructured":"Zhao S, et al. Molecular subtypes and precision treatment of triple-negative breast cancer. Ann Transl Med. 2020;8(7):499.","journal-title":"Ann Transl Med"},{"key":"2281_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1405491","volume":"14","author":"N Xiong","year":"2024","unstructured":"Xiong N, Wu H, Yu Z. Advancements and challenges in triple-negative breast cancer: A comprehensive review of therapeutic and diagnostic strategies. Front Oncol. 2024;14:1405491.","journal-title":"Front Oncol"},{"key":"2281_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061205","author":"KS You","year":"2021","unstructured":"You KS, et al. Dual inhibition of AKT and MEK pathways potentiates the anti-cancer effect of Gefitinib in triple-negative breast cancer cells. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13061205.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2281_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202105696","volume":"9","author":"AK Muller","year":"2022","unstructured":"Muller AK, et al. Mouse modeling dissecting macrophage-breast cancer communication uncovered roles of PYK2 in macrophage recruitment and breast tumorigenesis. Adv Sci (Weinh). 2022;9(9):e2105696.","journal-title":"Adv Sci (Weinh)"},{"issue":"7900","key":"2281_CR47","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41586-022-04439-0","volume":"603","author":"E Seung","year":"2022","unstructured":"Seung E, et al. A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells. Nature. 2022;603(7900):328\u201334.","journal-title":"Nature"},{"key":"2281_CR48","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.coi.2021.09.005","volume":"74","author":"L Poncette","year":"2022","unstructured":"Poncette L, Bluhm J, Blankenstein T. The role of CD4 T cells in rejection of solid tumors. Curr Opin Immunol. 2022;74:18\u201324.","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"2281_CR49","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/2326-6066.CIR-13-0216","volume":"2","author":"HJ Kim","year":"2014","unstructured":"Kim HJ, Cantor H. CD4 T-cell subsets and tumor immunity: The helpful and the not-so-helpful. Cancer Immunol Res. 2014;2(2):91\u20138.","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"2281_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112732","volume":"42","author":"MT Patterson","year":"2023","unstructured":"Patterson MT, et al. Tumor-specific CD4 T cells instruct monocyte fate in pancreatic ductal adenocarcinoma. Cell Rep. 2023;42(7):112732.","journal-title":"Cell Rep"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02281-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02281-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02281-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:42:24Z","timestamp":1781822544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02281-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2281"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02281-0","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were carried out in The Ohio State University\u2019s (OSU) animal facility in compliance with the guidelines and protocols approved by the OSU-IACUC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final manuscript and consent to its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publications"}},{"value":"RKG serves as a consultant for Guidepoint and co-founder for Embio Sys. Other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"112"}}